EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses

• Egile Nagusiak: Dinoop Ravindran Menon (Egilea), Yang Li (Egilea), Takeshi Yamauchi (Egilea), Douglas Grant Osborne (Egilea), Prasanna Kumar Vaddi (Egilea), Michael F Wempe (Egilea), Zili Zhai (Egilea), Mayumi Fujita (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2021-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Over the last decade, therapies targeting immune checkpoints, such as programmed death-1 (PD-1), have revolutionized the field of cancer immunotherapy. However, low response rates and immune-related adverse events remain a major concern. Here, we report that epigallocatechin gallate (EGCG), the most...